February 2026 saw a major biopharma acquisition, four key buyouts, and licensing deals in antibodies, small molecules, and ...
Higher drug exposure in women due to lower renal and hepatic clearance and body composition can increase efficacy but also toxicity, highlighting the need to reassess dosing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results